Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Dabrafenib halts growth of low-grade paediatric glioma

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 752

Dr Mark Kieran - Dana Farber Cancer Institue, Boston, USA

Dr Kieran speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago about results from a phase I/IIa study of dabrafenib in paediatric patients with V600 BRAF mutations in relapsed/refractory low grade glioma.

He outlines the staging of the trial, from dose determination in the phase I setting to subsequent treatment, noting variability in patients ± 12 years old.

Dr Kieran describes the limitation and even shrinkage of patients tumours as highly encouraging, with limited toxicity beyond skin irritation as a BRAF associated toxicity.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation